Search
  • All Journals
Advanced Search
Search articles by Title, Author, Keywords, DOI
Submit Manuscript
0.7Impact Factor
Advanced Search
MAP  >  Gastrointestinal Tumors
2021 Volume 8
Article Contents
Next Previous
CASE REPORT   Open Access    

Gastrointestinal Luminal Stenting: The Early US Experience with the Duodenal HANAROSTENT

  • a.

    Department of Medicine, Olive View-UCLA Medical Center, Sylmar, California, USA

  • b.

    David Geffen School of Medicine at UCLA, Los Angeles, California, USA

  • c.

    Department of Surgery, Olive View-UCLA Medical Center, Sylmar, California, USA

  • d.

    Division of Gastroenterology, Olive View-UCLA Medical Center, Sylmar, California, USA

More Information
  • Corresponding author: James H. Tabibian Division of Gastroenterology, Olive View-UCLA Medical Center 14445 Olive View Dr. 2B-182 Sylmar CA 91342 (USA) jtabibian@dhs.lacounty.gov
  • Self-expandable metal stents (SEMSs) are frequently utilized for palliation of malignant gastric and/or duodenal outlet obstruction (GDOO). Re-establishing luminal patency with accurate SEMS positioning while limiting migration and adjacent tissue injury is an important technical consideration and aim. The duodenal HANAROSTENT® was introduced in the USA in 2019 and developed with these challenges in mind. As the first center in the USA to deploy the duo­denal HANAROSTENT® in clinical practice, we herein examine our early experience with its use. Specifically, we describe 7 consecutive cases of malignant GDOO in which a duodenal HANAROSTENT® was placed for on-label use, defined as palliative treatment of malignant gastric and/or duodenal obstruction. All stents were 22 mm in diameter, with 5 being 90 mm and 2 being 120 mm in length. Technical and clinical success with duodenal HANAROSTENT® placement were achieved in all 7 cases (100%). In no case was stent adjustment required post-deployment. There were no stent-related adverse events, and no subsequent endoscopic procedures were necessary in any of the patients during a mean follow-up of 5 months (range 1–12 months). In summary, the duodenal HANAROSTENT® appears to perform well and be a promising alternative to other available duodenal SEMSs. As experience in the USA with this newly introduced duodenal SEMS grows, multicenter prospective data should be collected to better establish its relative safety and efficacy.

  • Cite this article

    Brian M. Fung, Brian E. Kadera, James H. Tabibian. 2021. Gastrointestinal Luminal Stenting: The Early US Experience with the Duodenal HANAROSTENT. Gastrointestinal Tumors. 8: doi: 10.1159/000510350
    Brian M. Fung, Brian E. Kadera, James H. Tabibian. 2021. Gastrointestinal Luminal Stenting: The Early US Experience with the Duodenal HANAROSTENT. Gastrointestinal Tumors. 8: doi: 10.1159/000510350
    shu

Figures(4)  /  Tables(1)

Download PDF

Article Metrics

Article views(535) PDF downloads(427)

Other Articles By Authors

Case Report   Open Access    

Gastrointestinal Luminal Stenting: The Early US Experience with the Duodenal HANAROSTENT

  • a.

    Department of Medicine, Olive View-UCLA Medical Center, Sylmar, California, USA

  • b.

    David Geffen School of Medicine at UCLA, Los Angeles, California, USA

  • c.

    Department of Surgery, Olive View-UCLA Medical Center, Sylmar, California, USA

  • d.

    Division of Gastroenterology, Olive View-UCLA Medical Center, Sylmar, California, USA

  • Corresponding author: James H. Tabibian Division of Gastroenterology, Olive View-UCLA Medical Center 14445 Olive View Dr. 2B-182 Sylmar CA 91342 (USA) jtabibian@dhs.lacounty.gov
  • Received: 21 April 2020
  • Accepted: 17 July 2020
  • Published online: 09 October 2020
Gastrointestinal Tumors  8,  Article number: 10.1159/000510350  (2021)  |  Cite this article

Abstract: Self-expandable metal stents (SEMSs) are frequently utilized for palliation of malignant gastric and/or duodenal outlet obstruction (GDOO). Re-establishing luminal patency with accurate SEMS positioning while limiting migration and adjacent tissue injury is an important technical consideration and aim. The duodenal HANAROSTENT® was introduced in the USA in 2019 and developed with these challenges in mind. As the first center in the USA to deploy the duo­denal HANAROSTENT® in clinical practice, we herein examine our early experience with its use. Specifically, we describe 7 consecutive cases of malignant GDOO in which a duodenal HANAROSTENT® was placed for on-label use, defined as palliative treatment of malignant gastric and/or duodenal obstruction. All stents were 22 mm in diameter, with 5 being 90 mm and 2 being 120 mm in length. Technical and clinical success with duodenal HANAROSTENT® placement were achieved in all 7 cases (100%). In no case was stent adjustment required post-deployment. There were no stent-related adverse events, and no subsequent endoscopic procedures were necessary in any of the patients during a mean follow-up of 5 months (range 1–12 months). In summary, the duodenal HANAROSTENT® appears to perform well and be a promising alternative to other available duodenal SEMSs. As experience in the USA with this newly introduced duodenal SEMS grows, multicenter prospective data should be collected to better establish its relative safety and efficacy.

  • About this article
    Cite this article
    Brian M. Fung, Brian E. Kadera, James H. Tabibian. 2021. Gastrointestinal Luminal Stenting: The Early US Experience with the Duodenal HANAROSTENT. Gastrointestinal Tumors. 8: doi: 10.1159/000510350
    Brian M. Fung, Brian E. Kadera, James H. Tabibian. 2021. Gastrointestinal Luminal Stenting: The Early US Experience with the Duodenal HANAROSTENT. Gastrointestinal Tumors. 8: doi: 10.1159/000510350
    shu

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return